DrugScope, the leading independent centre of expertise on drugs and drug policy, has today welcomed publication of the findings from the Advisory Council on the Misuse of Drugs (ACMD) review of ecstasy [1] [2].

Based on a review of the social and health harms of ecstasy, the ACMD recommends that the government reclassify the drug from Class A to Class B. The Council also advised that the government revise and widen access to public health messages and guidance on the drug's harms, particularly for young people.

Other key recommendations include:

-Parents, carers, teachers and those working in the criminal justice system should be informed about the risks of ecstasy and how these compare with those of other drugs.
-More research is required into the effects of ecstasy upon the brain.
-More research should be conducted regarding the nature and extent of ecstasy use among young people.

Responding to today's report, DrugScope Chief Executive Martin Barnes said:

"DrugScope welcomes the ACMD's report on ecstasy and we support all its recommendations. It is appropriate that drugs controlled under the Misuse of Drugs Act are subject to regular review, in order to ensure that decisions on drugs policy are informed by the latest and best evidence.

"DrugScope supports the ACMD's recommendation that ecstasy be reclassified to Class B. The advice is based on a thorough, objective and independent review of the latest evidence. Previous reviews of drug policy, not least a Home Affairs Select Committee report in 2002, have questioned the classification of ecstasy as a Class A drug. [3]

"The challenge is to ensure that any debate over ecstasy's classification is not perceived - or indeed misrepresented - as indicating that the drug is in any way 'safe'…